Novavax COVID-19 vaccine NVX-CoV2373 will be studied as a booster dose following two doses of the Pfizer-BioNTech vaccine
'NVX-CoV2373 has already shown strong immune responses against COVID-19 and its variants, and we look forward to further examining its role as a booster as we continue to explore how best to manage the continuing evolution of the coronavirus,' said
This stage of the investigator-initiated Phase 2 single-blind, randomized clinical trial will analyze reactogenicity and immune system responses to new combinations of vaccines in approximately 380 participants. All participants will have completed a two-dose schedule of the Pfizer-BioNTech vaccine at least three months before joining the trial. A third dose of either NVX-CoV2373 or the Pfizer-BioNTech vaccine will be administered as part of the trial.
Authorization in the
The Novavax COVID-19 vaccine (NVX-CoV2373) has not yet been authorized for use in the
Contact:
Tel: (240) 268-2022
Email: ir@novavax.com
(C) 2022 Electronic News Publishing, source